U.S. Hemostasis Valve Market Size, Share, Trends, Industry Analysis Report By Type (Hemostasis Valve Y- Connectors, Double Y- Connector Hemostasis Valves), By Application, By End Use

Description

List of Tables

The U.S. hemostasis valve market size is expected to reach USD 116.33 million by 2034, according to a new study by Polaris Market Research. The report "U.S. Hemostasis Valve Market Size, Share, Trends, Industry Analysis Report By Type (Hemostasis Valve Y- Connectors, Double Y- Connector Hemostasis Valves), By Application, By End Use; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

A hemostasis valve is a medical device used during catheter-based interventional procedures to prevent blood loss while allowing instruments to pass through vascular access sites.

The U.S. healthcare system is rapidly shifting toward minimally invasive surgery to reduce recovery time, hospital stays, and procedural complications. Interventional radiology and cardiology techniques are replacing traditional open surgeries, and these catheter-based approaches rely heavily on devices such as hemostasis valves to maintain blood control. The demand for tools that support these procedures is increasing as patient preference and healthcare policies favor less invasive care. Hemostasis valves are integral to ensuring both patient safety and procedural success in these fast-growing segments, making them a key component of the modern U.S. clinical toolkit and driving the U.S. hemostasis valve market market growth.

Medical institutions in the U.S. invest heavily in training programs and continuing education for healthcare professionals, especially in fields such as interventional cardiology, radiology, and endovascular surgery. These programs emphasize safe and efficient vascular access techniques, which include the use of hemostasis valves. The preference for high-quality valve solutions that improve procedural control and reduce complications such as blood loss and infection rise as clinical awareness grows. The educated and skilled medical workforce in the U.S. ensures high adoption rates of advanced medical devices and supports the ongoing expansion of the hemostasis valve market across various care settings.

U.S. Hemostasis Valve Market Report Highlights

In 2024, the hospital segment dominated with the largest share due to their advanced infrastructure, access to high patient volumes, and integration of interventional care units.

The angioplasty segment is expected to experience significant growth during the forecast period as angioplasty remains one of the most commonly performed interventional procedures in the U.S., especially for treating coronary artery disease.

A few key market players are Abbott; Antmed Corporation; Argon Medical Devices; B. Braun Melsungen AG; Boston Scientific Corporation; Lepu Medical Technology (Beijing) Co., Ltd.; Merit Medical Systems; Nipro; SCW Medicath Ltd.; Teleflex Incorporated; and TERUMO CORPORATION.

Polaris Market Research has segmented the U.S. hemostasis valve market report based on type, application, and end use:

By Type (Revenue - USD Million, 2020-2034)

Hemostasis Valve Y- Connectors

Double Y- Connector Hemostasis Valves

One- Handed Hemostasis Valves

Others

By Application (Revenue - USD Million, 2020-2034)

Angiography

Angioplasty

By End Use (Revenue - USD Million, 2020-2034)

Hospitals

Ambulatory Surgical Centers

Others

Product Code: PM5995

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. U.S. Hemostasias Valve Market Insights

4.1. U.S. Hemostasias Valve Market - Market Snapshot
4.2. U.S. Hemostasias Valve Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Number of Cardiovascular and Interventional Procedures
  - 4.2.1.2. Presence of Major Players
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Initial Cost
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Hemostasias Valve Market Trends
4.6. Value Chain Analysis

5. U.S. Hemostasias Valve Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Hemostasias Valve Market, by Type, 2020-2034 (USD million)
5.3. Hemostasis Valve Y- Connectors
- 5.3.1. U.S. Hemostasias Valve Market, by Hemostasis Valve Y- Connectors, by Region, 2020-2034 (USD million)
5.4. Double Y- Connector Hemostasis Valves
- 5.4.1. U.S. Hemostasias Valve Market, by Double Y- Connector Hemostasis Valves, by Region, 2020-2034 (USD million)
5.5. One- Handed Hemostasis Valves
- 5.5.1. U.S. Hemostasias Valve Market, by One- Handed Hemostasis Valves, by Region, 2020-2034 (USD million)
5.6. Others
- 5.6.1. U.S. Hemostasias Valve Market, by Others, by Region, 2020-2034 (USD million)

6. U.S. Hemostasias Valve Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Hemostasias Valve Market, by Application, 2020-2034 (USD million)
6.3. Angiography
- 6.3.1. U.S. Hemostasias Valve Market, by Angiography, by Region, 2020-2034 (USD million)
6.4. Angioplasty
- 6.4.1. U.S. Hemostasias Valve Market, by Angioplasty, by Region, 2020-2034 (USD million)

7. U.S. Hemostasias Valve Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Hemostasias Valve Market, by End Use, 2020-2034 (USD million)
7.3. Hospitals
- 7.3.1. U.S. Hemostasias Valve Market, by Hospitals, by Region, 2020-2034 (USD million)
7.4. Ambulatory Surgical Centers
- 7.4.1. U.S. Hemostasias Valve Market, by Ambulatory Surgical Centers, by Region, 2020-2034 (USD million)
7.5. Others
- 7.5.1. U.S. Hemostasias Valve Market, by Others, by Region, 2020-2034 (USD million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Abbott
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Antmed Corporation
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Argon Medical Devices
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. B. Braun Melsungen AG
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Boston Scientific Corporation
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Merit Medical Systems
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Nipro
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. SCW Medicath Ltd
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Teleflex Incorporated
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. TERUMO CORPORATION
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development